CVKD Form 4: CEO Quang Pham Disposes of 5,029 Shares Under 10b5-1 Plan

Rhea-AI Filing Summary

Cadrenal Therapeutics insider sale disclosure: Quang Pham, who serves as CEO and Chairman and is a director and 10% owner, reported open-market sales of the companys common stock on August 27 and August 28, 2025. On August 27 Mr. Pham sold 3,836 shares at a weighted average price of $13.99, reducing his reported direct beneficial ownership to 214,497 shares. On August 28 he sold 1,193 shares at a weighted average price of $13.99, reducing direct beneficial ownership to 213,304 shares. He also reports indirect ownership of 200,000 shares held by The PVBQ Living Trust, for which he is trustee. The filing indicates the transactions were made pursuant to a written plan consistent with Rule 10b5-1 and is signed by an attorney-in-fact on August 29, 2025.

Positive

• Disclosure compliance: Form 4 filed and signed, showing transparency of insider activity.
• 10b5-1 plan indicated: Transactions reported as pursuant to a written plan, which supports an affirmative defense against insider trading concerns.
• Continued substantial ownership: Reporting person retains 213,304 shares directly and 200,000 indirectly via trust.

Negative

• Insider sales occurred: 5,029 shares sold across August 27-28, 2025, reducing direct holdings.
• Reduction in direct ownership: Direct beneficial ownership declined from 214,497 to 213,304 shares following reported sales.

Insights

Securities Analyst

TL;DR: Insider sold a small portion of holdings under a 10b5-1 plan; disclosure is routine and not clearly material.

The Form 4 shows routine, open-market disposals totaling 5,029 shares across two days at a weighted average price of $13.99. Given Mr. Phams remaining direct ownership of 213,304 shares plus 200,000 indirectly held via a trust, the sales represent a modest reduction in direct holdings rather than a major divestiture. The filings 10b5-1 indication supports that these were prearranged trades, which reduces the implication of non-scheduled selling. For investors, the transaction documents adherence to disclosure rules but does not by itself signal a material change to control or ownership structure.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing planned insider sales while retaining substantial direct and indirect ownership.

The reporting person is CEO, Chairman and a 10% owner and disclosed both direct and indirect holdings. The check box indicating a purchase/sale pursuant to a written plan (10b5-1) is important from a governance perspective because it supports an affirmative defense against allegations of trading on material nonpublic information. The signature by an attorney-in-fact is properly executed. From a governance standpoint, the filing demonstrates procedural compliance but investors may still note insider liquidity and monitor future filings for pattern changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S		3,836	D	$13.99(1)	214,497	D
Common Stock	08/28/2025		S		1,193	D	$13.99(2)	213,304	D
Common Stock								200,000	I	The PVBQ Living Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold on the Transaction Date by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.03, inclusive, having a weighted average price as shown in column 4 of $13.99. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents shares of the Issuer's common stock sold on the Transaction Date by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.04, inclusive, having a weighted average price as shown in column 4 of $13.99. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Matthew K. Szot, Attorney-in-fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cadrenal (CVKD) insider Quang Pham sell and when?

Mr. Pham sold 3,836 shares on 08/27/2025 and 1,193 shares on 08/28/2025, totaling 5,029 shares.

At what price were the CVKD shares sold?

The reported weighted average price for the sales on both dates was $13.99 per share, with transaction price ranges disclosed in the filing.

What roles does the reporting person hold at Cadrenal (CVKD)?

The reporting person is listed as CEO and Chairman, a Director, and a 10% owner.

Does the Form 4 indicate the sales were prearranged under a trading plan?

Yes. The filer checked the box indicating the transactions were made pursuant to a written plan intended to satisfy Rule 10b5-1(c).

How many shares does Quang Pham beneficially own after these transactions?

After the reported transactions Mr. Pham reported 213,304 shares directly and 200,000 shares indirectly via The PVBQ Living Trust.